AA
KRYS icon

AlphaCentric Advisors’s Krystal Biotech KRYS Stock Holding History

AlphaCentric Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$723K Buy
1,945
+27
+1% +$8.07K 0.61% 48
2026
Q1 		$495K Buy
1,918
+105
+6% +$27.9K 0.49% 62
2025
Q4 		$447K Buy
+1,813
New +$382K 0.45% 68
2024
Q4 		$231K Buy
+1,474
New +$261K 0.23% 107

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AlphaCentric Advisors's KRYS Position: Q2 2026 in Review

AlphaCentric Advisors increased its Krystal Biotech (KRYS) stake by 1.4% in Q2 2026, buying an estimated $8.07K and bringing the position to 1,945 shares worth $723K. The position accounts for 0.61% of the portfolio, ranked #48.

AlphaCentric Advisors first reported a position in KRYS in Q4 2024 and has held it in 4 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • AlphaCentric Advisors held 1,945 shares of Krystal Biotech worth $723K as of Q2 2026.
  • AlphaCentric Advisors bought 27 Krystal Biotech shares in Q2 2026, an estimated $8.07K.
  • Krystal Biotech made up 0.61% of AlphaCentric Advisors's portfolio in Q2 2026, its #48 holding.
  • AlphaCentric Advisors first reported a position in Krystal Biotech in Q4 2024 and has held it in 4 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.